0000000000089767

AUTHOR

Shiwei Deng

showing 4 related works from this author

Dystrophin-deficiency increases the susceptibility to doxorubicin-induced cardiotoxicity

2007

Background and aim: The clinical use of doxorubicin (DOX) and other anthracyclines is limited by a dosage-dependent cardiotoxicity, which can lead to cardiomyopathy. The role of the individual genetic makeup in this disorder is poorly understood. Alterations in genes encoding cardiac cytoskeleton or sarcolemma proteins may increase the susceptibility to doxorubicin-related cardiotoxicity. Methods: Female dystrophin-deficient mice (MDX) and age-matched wild-type mice underwent chronic treatment with doxorubicin. Cardiac function and tissue damage were assessed by echocardiography and histopathology, respectively. Gene expression changes were investigated using microarrays. Results: DOX treat…

Cardiac function curveProgrammed cell deathPathologymedicine.medical_specialtyHeart DiseasesCytoskeleton organizationCardiomyopathyGene Expression030204 cardiovascular system & hematologyDystrophinMice03 medical and health sciences0302 clinical medicineRisk FactorsmedicineAnimalsDoxorubicinUltrasonography030304 developmental biology0303 health sciencesCardiotoxicityAntibiotics AntineoplasticSarcolemmabiologybusiness.industryGenetic VariationMicroarray Analysismedicine.disease3. Good healthDoxorubicinDisease Progressionbiology.proteinCancer researchFemaleDisease SusceptibilityCardiology and Cardiovascular MedicineDystrophinbusinessmedicine.drugEuropean Journal of Heart Failure
researchProduct

Topoisomerase II{alpha}-dependent and -independent apoptotic effects of dexrazoxane and doxorubicin.

2009

Abstract Coadministration of the iron chelator dexrazoxane reduces by 80% the incidence of heart failure in cancer patients treated with anthracyclines. The clinical application of dexrazoxane is limited, however, because its ability to inhibit topoisomerase IIα (TOP2A) is feared to adversely affect anthracycline chemotherapy, which involves TOP2A-mediated generation of DNA double-strand breaks (DSB). Here, we investigated the apoptotic effects of dexrazoxane and the anthracycline doxorubicin, alone and in combination, in a tumor cell line with conditionally regulated expression of TOP2A. Each drug caused apoptosis that was only partly dependent on TOP2A. Unexpectedly, dexrazoxane was found…

DrugCancer ResearchAnthracyclinemedicine.medical_treatmentmedia_common.quotation_subjectAntineoplastic AgentsApoptosisPharmacologyHistonesAntigens NeoplasmCell Line TumormedicineHumansDoxorubicinAdverse effectPoly-ADP-Ribose Binding Proteinsmedia_commonCaspase 7ChemotherapyChemistryCaspase 3Gene Expression ProfilingCancermedicine.diseaseGlutathioneDNA-Binding ProteinsGene Expression Regulation NeoplasticDNA Topoisomerases Type IIOncologyApoptosisDoxorubicinCancer researchDexrazoxaneTumor Suppressor Protein p53Razoxanemedicine.drugMolecular cancer therapeutics
researchProduct

Evolutionary History and Functional Characterization of the Amphibian Xenosensor CAR

2011

AbstractThe xenosensing constitutive androstane receptor (CAR) is widely considered to have arisen in early mammals via duplication of the pregnane X receptor (PXR). We report that CAR emerged together with PXR and the vitamin D receptor from an ancestral NR1I gene already in early vertebrates, as a result of whole-genome duplications. CAR genes were subsequently lost from the fish lineage, but they are conserved in all taxa of land vertebrates. This contrasts with PXR, which is found in most fish species, whereas it is lost from Sauropsida (reptiles and birds) and plays a role unrelated to xenosensing in Xenopus. This role is fulfilled in Xenopus by CAR, which exhibits low basal activity a…

AmphibianReceptors SteroidSubfamilyXenopusMolecular Sequence DataXenopusReceptors Cytoplasmic and NuclearCell LineEvolution MolecularEndocrinologyPhylogeneticsbiology.animalConstitutive androstane receptorAnimalsHumansAmino Acid SequenceRNA MessengerSauropsidaMolecular BiologyConstitutive Androstane ReceptorPhylogenyOriginal ResearchOligonucleotide Array Sequence AnalysisPregnane X receptorbiologyEcologyPregnane X ReceptorGeneral Medicinebiology.organism_classificationBiological EvolutionNuclear receptorGene Expression RegulationEvolutionary biologyReceptors CalcitriolSequence Alignment
researchProduct

Gp91phox-containing NAD(P)H oxidase increases superoxide formation by doxorubicin and NADPH

2006

Doxorubicin is a highly effective antineoplastic drug associated with a dose-dependent cardiotoxicity that may result in irreversible cardiomyopathy and heart failure. Gene variants of the superoxide-generating enzyme NAD(P)H oxidase have recently been associated with this phenotype. We investigated the mechanism of this association using lucigenin-enhanced chemiluminescence, spectrophotometry, electrochemical sensor, and electron paramagnetic resonance spectroscopy. Superoxide production was measured in female wild-type and NAD(P)H oxidase-deficient (gp91phox knockout) mice. The magnitude of the increase in superoxide production on the addition of doxorubicin was much higher in hearts of w…

LuminescenceGene ExpressionAntineoplastic AgentsPolymerase Chain ReactionBiochemistryMicechemistry.chemical_compoundSuperoxidesPhysiology (medical)medicineAnimalsDoxorubicinNADPH-Ferrihemoprotein ReductaseMice Knockoutchemistry.chemical_classificationCardiotoxicityOxidase testMembrane GlycoproteinsDose-Response Relationship DrugSuperoxideMyocardiumNADPH OxidasesMolecular biologyMice Inbred C57BLEnzymechemistryBiochemistryDoxorubicinNAD(P)H oxidaseNADPH Oxidase 2Knockout mouseNAD+ kinaseNADPmedicine.drugFree Radical Biology and Medicine
researchProduct